Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition

Rigel reports robust clinical data but lacks new financial disclosures or imminent catalysts.

What the company is saying

Rigel Pharmaceuticals is highlighting new and updated clinical data across its hematology pipeline, emphasizing the breadth of its ongoing studies and the upcoming presentations at the ASH Annual Meeting. The company frames its R289 Phase 1b study as progressing, with both dose escalation and expansion phases completed for 64 patients, and signals optimism about efficacy and safety in a difficult-to-treat MDS population. For TAVALISSE, Rigel underscores real-world and extension study results in ITP and wAIHA, focusing on improved platelet and hemoglobin responses, and reiterates the absence of new safety signals. The announcement uses specific patient numbers and percentages to support claims, but actual new efficacy data for R289 will only be presented at the ASH meeting. The tone is confident but measured, with chief medical officer Alison L. Hannah, M.D., quoted to reinforce the company's encouragement by evolving data. Safety profiles and adverse event rates for TAVALISSE and REZLIDHIA are detailed, but financial performance is not addressed.

What the data suggests

The Phase 1b R289 study enrolled 64 patients (33 in dose escalation, 31 in dose expansion) as of July 16, 2026, with the majority having high transfusion burden at baseline, but no specific efficacy or transfusion reduction data are disclosed yet. For TAVALISSE, a real-world ITP analysis of 90 patients showed that 81.6% of 38 patients with available data during months 7-12 achieved platelet counts ≥50 × 10³/µL, up from 33.3% at baseline, suggesting a strong response to combination therapy. In Japan, interim post-marketing surveillance of 799 patients found platelet counts increased within two weeks and were sustained at 12 months in a subset. In wAIHA, more than 50% of 71 patients in a long-term extension study had durable hemoglobin responses through Week 104. Safety data for TAVALISSE show diarrhea in 31% of patients (severe in 1%), neutropenia in 6% (febrile in 1%), and other serious adverse reactions at 1-2%. For REZLIDHIA in AML, differentiation syndrome occurred in 16% (grade 3/4 in 8%, fatal in 1%), with 76% of affected patients recovering, and hepatotoxicity in 23% (grade 3/4 in 13%). The American Cancer Society projects 22,720 new AML cases in the US in 2026, about 1% of adult cancers. The data is detailed and supports most clinical claims, but the announcement lacks any financial metrics, period comparisons, or commercial performance indicators.

Analysis

The announcement is largely factual and data-driven, providing detailed numerical outcomes from ongoing and completed clinical studies, including patient counts, response rates, and adverse event frequencies. Most claims are realised and supported by disclosed data, with only a small fraction (notably the upcoming ASH presentations and pending updated efficacy data for R289) being forward-looking. The tone is positive but not exaggerated, and there is no evidence of narrative inflation or overstatement relative to the disclosed results. No large capital outlay or long-dated, uncertain returns are mentioned. The absence of financial metrics (revenue, profit, cash flow) means the signal cannot be stronger than weak_positive, but the clinical data is robust and specific. The gap between narrative and evidence is minimal, with only minor promotional language (e.g., 'encouraged by our evolving data') that does not materially inflate the signal.

Risk flags

• ●The absence of disclosed financial data or commercial performance metrics means investors cannot assess revenue trends, cash runway, or profitability, increasing uncertainty about near-term financial health.
• ●Efficacy data for the R289 dose expansion phase is not disclosed in this release and will only be presented at the ASH meeting, leaving a gap in visibility on whether the drug candidate is meeting key endpoints.
• ●Safety data for TAVALISSE and REZLIDHIA show notable rates of adverse events, including 31% diarrhea and 6% neutropenia for TAVALISSE, and 16% differentiation syndrome for REZLIDHIA, which could limit broader adoption or lead to regulatory scrutiny if not managed.
• ●The clinical results for TAVALISSE in ITP and wAIHA are promising but are based on interim or subset analyses (e.g., 81.6% response in only 38 of 90 ITP patients with available data), which may not generalize to all treated patients or translate into commercial success.
• ●No new regulatory or commercial milestones are announced, so the timeline to potential revenue growth or value realization remains uncertain beyond the upcoming data presentations.

Bottom line

Rigel's announcement delivers detailed clinical and safety data for R289, TAVALISSE, and REZLIDHIA, demonstrating progress in patient enrollment and response rates across multiple hematologic indications. The most immediate catalyst is the presentation of updated R289 efficacy data at the ASH meeting in December 2026, but until those results are public, investors lack visibility on whether the drug can drive future value. The absence of any financial or commercial metrics means the announcement is not actionable from a revenue or profit perspective. Safety profiles for both TAVALISSE and REZLIDHIA include significant adverse event rates that could impact uptake. Investors should focus on the forthcoming ASH data for R289 and watch for any subsequent regulatory or commercial updates. The key takeaway is that Rigel is advancing its pipeline, but the path to financial impact remains unproven in this disclosure.

Announcement summary

(NASDAQ:RIGL) Rigel Pharmaceuticals, Inc. announced that updated data from the ongoing Phase 1b clinical study of R289, a dual IRAK1/4 inhibitor, in patients with relapsed or refractory lower-risk myelodysplastic syndrome (MDS) will be presented in an oral session at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition on December 12, 2026. The Phase 1b study enrolled 64 patients as of July 16, 2026, with 33 patients in the dose escalation phase and 31 in the dose expansion phase. The majority of these patients had high transfusion burden (HTB) disease at baseline. Updated efficacy and safety data from the dose expansion phase will be presented, including preliminary results on reduction of transfusion dependence. Three poster presentations will also be featured at ASH for TAVALISSE® (fostamatinib disodium hexahydrate) in patients with immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). In a real-world analysis of 90 ITP patients receiving fostamatinib plus a thrombopoietin receptor agonist (TPO-RA), 81.6% of 38 patients with available measurements during months 7-12 had platelet counts ≥50 × 10³/µL, up from 33.3% at baseline. An interim analysis of 799 patients in post-marketing surveillance in Japan showed platelet counts increased within two weeks of fostamatinib initiation, with responses maintained at 12 months in a subset of patients. In a long-term extension study of 71 wAIHA patients treated with fostamatinib, durable hemoglobin responses were observed in more than 50% of patients through Week 104. The safety profile of fostamatinib in these studies was consistent with previous findings, with no new safety signals identified. TAVALISSE is indicated for thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to previous treatment. Diarrhea occurred in 31% of patients and severe diarrhea in 1% of patients treated with TAVALISSE. Neutropenia occurred in 6% of patients, with febrile neutropenia in 1%. Serious adverse reactions in ITP double-blind studies included febrile neutropenia, diarrhea, pneumonia, and hypertensive crisis, each in 1% of patients. Other severe adverse reactions included dyspnea and hypertension (2%), and several others at 1%. REZLIDHIA (olutasidenib) is indicated for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation. Differentiation syndrome occurred in 16% of patients treated with REZLIDHIA, with grade 3 or 4 events in 8% and fatalities in 1%. Of 25 patients with differentiation syndrome, 76% recovered after treatment or dose interruption. Hepatotoxicity occurred in 23% of patients, with 13% experiencing grade 3 or 4 events. The American Cancer Society estimates about 22,720 new cases of AML in the United States in 2026, accounting for about 1% of all adult cancers.

Disagree with this article?